Drawn by a passion for SnAP technology and all the innovative potential that it represents, our team represents an impressive and remarkable blend of breadth and depth of experience. We are committed to carving a new space in antibody design and improving the lives of patients and their families with potentially more efficacious, safer, and cost-efficient antibody-based products.
Martin Latterich, Ph.D.
President, CEO, Director
Dr. Latterich is a biotechnology executive with a strong mix of corporate leadership and academic experience.
Previously, he served as SVP of Technical Operation and Officer for Histogen (NASDAQ: HSTO), a publicly traded, clinical-stage biotechnology firm focusing on regenerative medicine, inflammatory disorders, and infectious disease. His past professional affiliations include the Salk Institute as Assistant Professor, Diversa (NASDAQ: VRNM) as Principal Scientist, Illumina (NASDAQ: ILMN) as
Director of Proteomics, McGill Medical School and the University of Montreal as Associate Professor, the Proteogenomics Research Institute for Systems Medicine as Professor, the Nicholas Conor Institute as CSO and co-founder, and ProterixBio, Inc. (formerly known as BioScale, Inc.) as CSO. Dr. Latterich's expertise is in the establishment and growth of science-focused research initiatives and commercial organizations, technology evaluation/acquisition, partnerships, and corporate leadership.
Author of 40 publications mostly in premier, peer-reviewed journals and one book; Editor-in-Chief of Proteome Science from 2002 to 2019. Dr. Latterich received grant funding from NIH, HFSP, March of Dimes, Pew Foundation, Genome Canada, Genome Quebec, CIHR and CFI. Dr. Latterich is a 1998 Pew Scholar and has held a prestigious Tier I Canada Research Chair at McGill University. He
performed post-doctoral training in the laboratory of the Nobel Laureate Randy Schekman at UC Berkeley. He received a B.Sc. in Molecular Biology and Biochemistry, as well as a Ph.D. from Durham University in the UK.
Robert P. McKenzie
Executive Vice President of Business Development, Director
Mr. McKenzie brings more than 25 years of experience in worldwide business development, as well as general and operational management expertise in sales and marketing, primarily in the technology industry.
Most recently, he was vice president at Amdocs, a global leader in outsourced business services, where he oversaw key global accounts in the company's Broadband, Cable and Satellite division, and was responsible for strategic planning in the cable and satellite industry, product development, business development and program delivery.
Mr. McKenzie is an internationally recognized business development professional, having orchestrated billion-dollar, transnational deals within the telecom and media industries.
He earned his B.A. in Business Economics from the University of California at Santa Barbara and serves on the board of Stanford Youth Solutions.
Chief Scientific Officer, Director
Dr. David Stover, Ph.D. is an accomplished pharmaceutical researcher and scientist with more than 25 years of experience in both small-molecule and biologics drug discovery and development.
Most recently, he served as head of Agensys, Inc., an Astellas Pharma affiliate focused on antibody and antibody drug conjugate development, where he led a team of 240 employees in the research, clinical manufacturing and development of five investigational new drugs and four clinical proof of concepts during a 5-year period. Dr. Stover also founded the Oncology Biologics department at Novartis, where he served as its director, developing three clinical product candidates. Previously, he held the position of vice president of drug discovery at MDS Proteomics, where he managed research sites in Cambridge., Mass., Charlottesville, Va., and Toronto. Earlier in his career, Dr. Stover was the first employee and director of biochemistry at Kinetix Pharmaceuticals, a small-molecule kinase inhibitor company that was acquired by Amgen in 2000.
Dr. Stover earned his Ph.D. in biochemistry at the University of Washington and holds a Bachelor of Science degree in zoology from Duke University.
Michael Goldberg, M.B.A.
Mr. Goldberg is currently a partner and director at Bain & Company, based in its Los Angeles office.
He previously held senior positions at Deloitte Consulting and Hughes Aircraft. Mr. Goldberg is a management and strategy consultant whose expertise lies in helping companies develop and implement competitive and sustainable growth strategies, as well as dramatically improving operational performance. Throughout his career, Mr. Goldberg has led significant consulting efforts in the areas of corporate growth and new market development, competitive analysis, cost reduction, asset efficiency, mergers and acquisitions, and information technology strategy, specializing in highly regulated industries, with a particular focus in aerospace and defense.
Mr. Goldberg holds an M.B.A. from the Anderson School of Business at the University of California at Los Angeles, and graduated phi beta kappa with a B.A. in economics from Occidental College. He also served as a trustee on the Occidental College Board of Trustees and chaired Occidental College's alumni fund. He currently serves as a trustee for the La Cañada Educational Foundation endowment.
Stephanie Hsieh, J.D., M.B.A.
Stephanie Hsieh currently serves as the Executive Director of Biocom California’s Los Angeles office, having earlier served on its Advisory Board. Biocom California is a $20 million, 1600 member, non-profit trade association for the life science industry. She is spearheading the transformation of the Greater Los Angeles Region into a premier life science hub.
Prior to joining Biocom California, Stephanie co-founded and grew Meditope Biosciences from academic technology concept to a preclinical stage oncology company. She created a successful patent portfolio strategy and raised $6.4 million in early-stage financing. Her career in biopharma spans 30 years, having held both corporate and law firm positions developing an expertise at the intersection of new product planning strategies and patent law and a reputation for building consensus by reframing issues and making complex information relatable.
In 2021, Stephanie was recognized by the LA Business Journal as one of the “most influential leaders and impactful executives in Los Angeles.” She graduated magna cum laude, Phi Beta Kappa, and Sigma Xi from Wellesley College, received a JD from Columbia Law School as a Harlan Fiske Stone Scholar, and holds an MBA from Stanford’s Graduate School of Business.
George Prendergast Ph.D.
Dr. Prendergast is an accomplished cancer researcher with experience in the pharmaceutical industry as well as in academia, recognized for his expertise in cancer biology, signal transduction and molecular therapeutics.
Throughout his career, he has become known as an innovator who has the ability to translate basic research findings toward clinical application, most recently in developing a novel drug-like therapy to improve the immune response against a cancer.
He currently is president and CEO of the Lankenau Institute for Medical Research and a professor in the Department of Pathology, Anatomy & Cell Biology, Jefferson Medical School, Thomas Jefferson University. He also is co-director of the Program in Cell Biology & Signaling, KCC, Thomas Jefferson University.
Dr. Prendergast has contributed articles to numerous publications in the field of cancer research and is inventor or co-inventor on a number of published or pending patents.